Eli Lilly’s long-awaited oral GLP-1 therapy, orforglipron, helped participants shed an average of 12.4% of their body weight over 72 weeks—an impressive result for a once-daily pill, yet below the 14.9% achieved by Novo Nordisk’s injectable Wegovy. While investors had hoped Lilly’s tiny molecule would match or best the injectable standard, the data nonetheless mark a major advance in convenience and accessibility for obesity treatment.

Why an oral pill matters

• Needle fatigue: Many patients find daily or weekly injections a barrier to long-term adherence. Surveys show most people would choose a pill over a shot.

• Manufacturing edge: As a small-molecule drug, orforglipron can be produced at scale more easily than peptide injections, promising steadier supply and potentially lower costs.

Trial highlights

• Who: Over 3,000 adults (non-diabetic) with overweight or obesity and related health issues.

• What: High-dose group (36 mg once daily) lost 12.4% vs. 0.9% on placebo. A mid-dose (6 mg) still delivered 7.8% weight loss.

• Side effects: About one-third of high-dose patients experienced nausea, and nearly one-quarter had vomiting—higher than expected. Drop-out rate was just over 10%, with no liver safety signals.

Investor reaction
Lilly shares dipped about 9% in premarket trading as markets digested the miss against Wegovy’s headline-grabbing results. Novo Nordisk stock jumped 8%, with analysts calling this outcome the “best-case scenario for Novo,” easing fears of an imminent oral challenger.

Lilly’s perspective
CEO David Ricks struck an optimistic tone: “We’re encouraged by these results,” he said on an investor call, stressing the company’s mission to deliver a powerful, easy-to-take GLP-1 medicine. Kenneth Custer, head of Lilly’s cardiometabolic division, added that early intervention and chronic management could be transformed by an oral option.

Beyond pounds lost
Orforglipron also improved key heart-health markers—lowering cholesterol, triglycerides, and blood pressure—echoing the dual benefits seen with injectables like Wegovy (which is already approved to reduce major cardiovascular events).

What’s next?

• Regulatory push: Lilly plans to submit orforglipron filings globally with urgency, aiming for approval that could come as early as next year.

• Supply readiness: Manufacturing is already underway to build inventory and avoid the shortages that plagued early GLP-1 injectables.

• Ongoing data: Full trial results will be unveiled at a major European diabetes conference next month, where more detail on safety and subgroups is expected.

Bottom line
While orforglipron doesn’t quite match the weight-loss peaks of Wegovy, it brings a game-changing convenience that could expand access to millions who’ve shrugged off injections. In a market expected to reach $150 billion by the early 2030s, having both pill and shot options may be the real win for patients—and for healthcare systems wrestling with the global obesity epidemic.